Boehringer Ingelheim Corporation and Eli Lilly and Company Release: New Poll Highlights Treatment Priorities of European Primary Care Physicians When Managing Type 2 Diabetes

INGELHEIM, Germany & INDIANAPOLIS, Ind.--(BUSINESS WIRE)--Boehringer Ingelheim and Eli Lilly and Company today announced results from a poll conducted with more than 1,000 primary healthcare professionals (HCPs) across eight European countries surveyed on their current perceptions and challenges in treating people with Type 2 Diabetes (T2D) across Europe.

Help employers find you! Check out all the jobs and post your resume.